Crapo, Bennet, Cardin, and Scott introduce legislation to expand coverage of MCEDs

What NHS-Galleri taught us—and what it didn’t

On May 30, GRAIL reported the full results of the NHS-Galleri trial in an oral presentation at the ASCO Annual Meeting.

June 18, 2026

The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies

The NHS-Galleri trial presented at ASCO was the largest, prospective, randomized trial of a multicancer early detection test (MCED) to date. The study enrolled approximately 143,000 asymptomatic adults (ages 50-77) and was the first of its kind to assess clinical utility of an MCED test for cancer screening.

June 18, 2026

Vol.52 No.24

By Bryan Bassig, Catherine R. Marinac, David M. Routman, Elizabeth K. O'Donnell, Jennifer Keating Litton, Karthik V. Giridhar, Kennedy Ng Yao Yi, Kurt Giles, Nima Nabavizadeh, Ora K. Gordon, Rebecca Kaltman and Shawn Kothari

Clinical Roundup

GRAIL reports full results from NHS-Galleri trial at ASCO

GRAIL Inc. presented more detailed results of the NHS-Galleri trial in an oral presentation at the 2026 American Society of Clinical Oncology annual meeting.

June 05, 2026

Vol.52 No.22

Cancer Policy

House member introduces bill to increase funding for MCD testing of firefighters

Rep. Josh Gottheimer (D-NJ) introduced the FIRE Cancer Act on Feb. 27. The piece of legislation seeks to increase grant dollars available to local fire departments, specifically earmarked for cancer prevention, “including providing multi-cancer early detection testing or other forms of preventative tests.”

NHS-Galleri MCD trial fails to meet primary endpoint of stage shift

High-level results from the randomized, controlled NHS-Galleri trial, which is evaluating GRAIL’s multi-cancer screening test, Galleri, over three years in 142,000 participants aged 50 to 77, reveals that the trial did not meet its primary endpoint of shifting cancer diagnosis from advanced stages (3 and 4) to earlier stage (1 and 2).

Super Bowl ad by Hims & Hers features GRAIL’s Galleri MCD test

A Super Bowl LX commercial by Hims & Hers, a controversial direct-to-consumer medication platform, featured the company’s new offering: Galleri, a multi-cancer detection test produced by GRAIL Inc.

February 13, 2026

Vol.52 No.06

By Jacquelyn Cobb and Sara Willa Ernst